Neurogenesis-Targeting Therapies for Neurodegenerative Diseases

Neurogenesis-Targeting Therapies for Neurodegenerative Diseases

Pathway Diagram

Introduction

Neurogenesis Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Neurogenesis-Targeting Therapies for Neurodegenerative Diseases

Pathway Diagram

Introduction

Neurogenesis Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Neurogenesis, the process of generating new [neurons](/entities/neurons) from neural stem cells, occurs primarily in two regions of the adult mammalian brain: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the [hippocampus](/brain-regions/hippocampus). These neural stem cells (NSCs) can proliferate, differentiate, and integrate into existing neural circuits, offering potential for brain repair in neurodegenerative conditions. [@gage2000]

In neurodegenerative diseases, endogenous neurogenesis is often impaired or insufficient to compensate for progressive neuronal loss. Various factors contribute to this impairment: chronic neuroinflammation, oxidative stress, protein aggregate accumulation, and age-related decline in growth factor signaling. Neurogenesis-targeting therapies aim to overcome these barriers by: [@eriksson1998]

The therapeutic goal is not merely to increase the number of new neurons, but to ensure their proper differentiation, migration, and functional integration into neural circuits relevant to each disease context. [@zhao2008]

Mechanisms of Action

Growth Factor-Based Approaches

• Brain-Derived Neurotrophic Factor (BDNF): Promotes neuronal survival and differentiation
• Fibroblast Growth Factor (FGF): Stimulates NSC proliferation
• Vascular Endothelial Growth Factor (VEGF): Supports neurovascular coupling
• Insulin-like Growth Factor (IGF-1): Enhances neurogenesis and neuronal maturation

Small Molecule Agonists

• Phosphodiesterase inhibitors: Enhance cAMP signaling to promote neurogenesis
• AMPA receptor modulators: Increase neuronal activity-dependent neurogenesis
• Notch pathway inhibitors: Push NSCs toward neuronal differentiation

Cell-Based Therapies

• Neural stem cell transplantation: Direct delivery of NSCs to affected brain regions
• Induced pluripotent stem cells (iPSCs): Patient-derived neurons for replacement therapy

Clinical Applications

Alzheimer's Disease

Neurogenesis targeting in AD focuses on the hippocampus, where neuronal loss contributes to memory impairment. Strategies include: [@kempermann2015]

• Exercise-induced neurogenesis enhancement
• Pharmacological approaches (e.g., antidepressive agents with neurogenic effects)
• Dietary interventions (e.g., caloric restriction, flavonoids)

Parkinson's Disease

In PD, neurogenesis approaches aim to replace dopaminergic neurons in the substantia nigra: [@sorrells2018]

• Subventricular zone stimulation
• Transplantation of dopamine-producing cells
• Growth factor delivery to support endogenous repair

Stroke Recovery

Post-stroke neurogenesis is naturally elevated, and therapeutic approaches aim to enhance this response:

• Exercise and rehabilitation
• Pharmacological enhancement of NSC migration to damaged areas
• Cell-based therapies for circuit reconstruction

See Also

• [Neural Stem Cell Therapy](/therapeutics/neural-stem-cell-therapy)
• [iPSC Therapy](/therapeutics/ipsc-therapy-neurodegeneration)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [Brain-Derived Neurotrophic Factor](/entities/bdnf)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntington-disease)
• [Stroke](/diseases/stroke)

External Links

• [Nature: Neurogenesis in the adult brain](https://www.nature.com/subjects/adult-neurogenesis)
• [NIH: Neural Stem Cell Research](https://stemcells.nih.gov/)

Background

The study of Neurogenesis Targeting Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: Cell-type-specific essential genes
• [Epigenetic Memory Reprogramming for Alzheimer&#x27;s Disease](/hypothesis/h-29ef94d5) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BDNF, CREB1, synaptic plasticity genes
• [Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Neurogenesis-Targeting Therapies for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis: